Compared to Trastuzumab which required high antibody concentration to achieve cytotoxicity in tumor cells, anti-HER2-SHR169265 ADCs induced much stronger cytotoxicity in HER2-expressing cells without obvious effect on HER2-negative cells (MDA-MB-468). The gene discussed is ERBB2; the disease is neoplasm.